FHTX
Foghorn Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.14
−1.43%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.22
- Revenue estimate
- $7.1M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.10
- EPS estimate
- -$0.24
- Revenue actual
- $16.1M
- Revenue estimate
- $6.8M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +11.5%
- Revenue beats (12Q)
- 5
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.24 | -$0.10 | Beat 59.18% | $16.1M |
| May 7, 2026 | -$0.28 | -$0.29 | Miss -3.57% | $3.3M |
| Mar 11, 2026 | -$0.26 | -$0.34 | Miss -28.79% | $9.2M |
| Nov 5, 2025 | -$0.31 | -$0.25 | Beat 19.35% | $8.2M |
| Mar 6, 2025 | -$0.43 | -$0.30 | Beat 30.23% | $2.9M |
| Aug 8, 2024 | -$0.60 | -$0.45 | Beat 25.00% | $6.9M |
| Mar 7, 2024 | -$0.79 | -$0.57 | Beat 27.85% | $5.8M |
| Nov 2, 2023 | -$0.72 | -$0.34 | Beat 52.78% | $17.5M |
| Aug 4, 2023 | -$0.73 | -$0.70 | Beat 4.11% | $5.6M |
| Mar 9, 2023 | -$0.59 | -$0.69 | Miss -16.95% | $4.2M |
| Mar 10, 2022 | -$0.74 | -$0.77 | Miss -4.05% | $713.0K |
| Aug 10, 2021 | -$0.63 | -$0.63 | In line | $279.0K |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026